Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new�…

BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease�…

Background Inflammation and hyperlipidaemia jointly contribute to atherothrombotic
disease. However, when people are treated with intensive statin therapy, the relative�…

Elevated triglycerides and non-high-density lipoprotein cholesterol (HDL-C) are risk factors
for atherosclerotic cardiovascular disease (ASCVD). ARO-ANG3 is an RNA interference�…

A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors
such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led�…

Aims Cholesterol carried in triglyceride-rich lipoproteins, also called remnant cholesterol, is
being increasingly acknowledged as an important causal risk factor for atherosclerosis�…

Background Reducing the levels of triglycerides and triglyceride-rich lipoproteins remains
an unmet clinical need. Olezarsen is an antisense oligonucleotide targeting messenger�…

Pegozafermin, a long-acting glycopegylated analog of human fibroblast growth factor 21, is
in development for the treatment of severe hypertriglyceridemia (SHTG) and nonalcoholic�…

Cardiovascular disease is the leading cause of death in women and men globally, with most
due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30�…

Background Some observational studies found that dyslipidaemia is a risk factor for non-
alcoholic fatty liver disease (NAFLD), and lipid-lowering drugs may lower NAFLD risk�…